Taysha Gene Therapies, Inc. TSHA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $276.58M+137% | $319.77M+130% | $297.34M+88.6% | $312.76M+81.1% | $116.59M-6.0% | ||
| $449K0.0% | $449K0.0% | $449K0.0% | $449K0.0% | $449K0.0% | ||
| $14.87M+14.3% | $13.31M-1.5% | $11.52M-19.7% | $12.78M-22.3% | $13.01M-41.4% | ||
| —— | —— | —— | —— | —— | ||
| $282.25M+134% | $324.65M+128% | $299.95M+85.7% | $316.26M+77.2% | $120.71M-7.6% | ||
| $6.45M-10.9% | $6.74M-10.0% | $6.81M-10.6% | $6.96M-33.8% | $7.24M-32.3% | ||
| $9.16M+13.3% | $9.44M+12.6% | $7.46M-14.0% | $7.77M-13.4% | $8.08M-12.8% | ||
| $181K-3.7% | $183K-15.7% | $184K-16.4% | $186K-35.4% | $188K-38.2% | ||
| $300.35M+117% | $343.32M+114% | $316.55M+75.7% | $333.33M+66.3% | $138.36M-9.6% | ||
| $23.99M+11.2% | $23.75M-14.0% | $21.07M-30.7% | $20.56M-37.7% | $21.57M-38.4% | ||
| $15.53M+44.4% | $20.28M+57.7% | $17.71M+40.5% | $12.15M+2.3% | $10.76M-20.7% | ||
| —— | —— | $5.49M-53.5% | $5.49M-59.6% | $7.47M-49.2% | ||
| $1.55M+10.2% | $1.49M0.0% | $1.25M-13.2% | $1.33M-4.1% | $1.41M+5.4% | ||
| $275K-31.6% | $379K-3.1% | $423K+11.0% | $412K+11.1% | $402K+11.0% | ||
| $20.1M-10.9% | $26.55M+1.2% | $28.63M-2.4% | $25.35M-25.8% | $22.56M-41.6% | ||
| $48.96M+15.3% | $50.11M+14.0% | $50.85M+18.3% | $41.05M+8.5% | $42.45M+4.8% | ||
| $17.77M+3.9% | $18.17M+4.7% | $16.51M-7.0% | $16.81M-7.3% | $17.09M-7.6% | ||
| $275K-59.4% | $379K-50.8% | $480K-44.3% | $579K-39.1% | $677K-34.8% | ||
| $19.32M+4.4% | $19.66M+4.3% | $17.75M-7.5% | $18.13M-7.1% | $18.5M-6.7% | ||
| $1.58M+31.8% | $1.55M+18.6% | $1.58M+15.6% | $1.4M+1.2% | $1.2M-20.1% | ||
| $88.41M+6.1% | $96.38M+8.5% | $97.57M+6.7% | $84.6M-7.6% | $83.3M-16.0% | ||
| $3K+50.0% | $3K+50.0% | $3K+50.0% | $3K+50.0% | $2K0.0% | ||
| $964.67M+41.6% | $958.43M+41.4% | $903.58M+33.9% | $900.14M+35.5% | $681.18M+15.2% | ||
| -$753.71M-20.8% | -$711.3M-18.1% | -$683.45M-17.1% | -$650.72M-16.6% | -$623.83M-16.2% | ||
| $985K+143% | -$192K+95.2% | -$1.14M— | -$699K— | -$2.29M— | ||
| $211.94M+285% | $246.94M+245% | $218.99M+147% | $248.73M+128% | $55.06M+2.2% | ||
| $300.35M+117% | $343.32M+114% | $316.55M+75.7% | $333.33M+66.3% | $138.36M-9.6% | ||
| $181K-3.7% | $183K-15.7% | $184K-16.4% | $186K-35.4% | $188K-38.2% | ||
| $9.16M+13.3% | $9.44M+12.6% | $7.46M-14.0% | $7.77M-13.4% | $8.08M-12.8% | ||
| $9.16M+13.3% | $9.44M+12.6% | $7.46M-14.0% | $7.77M-13.4% | $8.08M-12.8% | ||
| $181K-3.7% | $183K-15.7% | $184K-16.4% | $186K-35.4% | $188K-38.2% | ||
| $9.16M+13.3% | $9.44M+12.6% | $7.46M-14.0% | $7.77M-13.4% | $8.08M-12.8% | ||
| $181K-3.7% | $183K-15.7% | $184K-16.4% | $186K-35.4% | $188K-38.2% | ||
| $15.53M+44.4% | $20.28M+57.7% | $17.71M+40.5% | $12.15M+2.3% | $10.76M-20.7% | ||
| $68.55M+11.2% | $70.14M+10.4% | $69.08M+9.6% | $59.76M+2.5% | $61.63M+0.4% | ||
| $3K+50.0% | $3K+50.0% | $3K+50.0% | $3K+50.0% | $2K0.0% | ||
| $275K-31.6% | $379K-3.1% | $423K+11.0% | $412K+11.1% | $402K+11.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Taysha Gene Therapies, Inc. cover its short-term obligations?
- Its current ratio is 14.04 — current assets exceed current liabilities.
- Where does Taysha Gene Therapies, Inc.'s balance sheet data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.